C. Knouff, et.al., Apo E structure determines VLDL clearance and atherosclerosis risk in mice., The Journal of clinical investigation, 1999, 103

http://rdf.ncbi.nlm.nih.gov/pubmed/10359567

C. Knouff, et.al., Apo E structure determines VLDL clearance and atherosclerosis risk in mice., The Journal of clinical investigation, 1999, 103

pubmed

allele

http://purl.org/net/cito/citesAsAuthority

• Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2158398

表現型アノテーション

http://purl.org/net/cito/citesAsAuthority

• decreased circulating VLDL cholesterol level_Apoe<tm2(APOE*3)Mae>/Apoe<tm2(APOE*3)Mae>
  http://metadb.riken.jp/0005146I129P2OlaHsdC57BL6JApoetm2APOE3MaeApoetm2APOE3MaeApoetm2APOE3Mae
• decreased circulating HDL cholesterol level_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0000186I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae
• decreased susceptibility to atherosclerosis_Apoe<tm2(APOE*3)Mae>/Apoe<tm2(APOE*3)Mae>
  http://metadb.riken.jp/0005341I129P2OlaHsdC57BL6JApoetm2APOE3MaeApoetm2APOE3MaeApoetm2APOE3Mae
• increased circulating triglyceride level_Apoe<tm2(APOE*3)Mae>/Apoe<tm2(APOE*3)Mae>
  http://metadb.riken.jp/0001552I129P2OlaHsdC57BL6JApoetm2APOE3MaeApoetm2APOE3MaeApoetm2APOE3Mae
• increased circulating VLDL triglyceride level_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0003975I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae
• increased susceptibility to atherosclerosis_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0005339I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae
• increased circulating HDL cholesterol level_Apoe<tm2(APOE*3)Mae>/Apoe<tm2(APOE*3)Mae>
  http://metadb.riken.jp/0001556I129P2OlaHsdC57BL6JApoetm2APOE3MaeApoetm2APOE3MaeApoetm2APOE3Mae
• abnormal lipid level_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0001547I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae
• decreased circulating VLDL triglyceride level_Apoe<tm2(APOE*3)Mae>/Apoe<tm2(APOE*3)Mae>
  http://metadb.riken.jp/0003976I129P2OlaHsdC57BL6JApoetm2APOE3MaeApoetm2APOE3MaeApoetm2APOE3Mae
• decreased circulating triglyceride level_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0002644I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae
• increased circulating VLDL cholesterol level_Apoe<tm3(APOE*4)Mae>/Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/0005145I129P2OlaHsdC57BL6Apoetm3APOE4MaeApoetm3APOE4MaeApoetm3APOE4Mae

class

http://purl.org/net/cito/citesAsAuthority

• Apoe<tm3(APOE*4)Mae>
  http://metadb.riken.jp/db/mgi_rdf/MGI:2158398